PTCT
PTC Therapeutics, Inc. NASDAQ Listed Jun 20, 2013$64.42
Mkt Cap $5.3B
52w Low $39.53
51.9% of range
52w High $87.50
50d MA $67.66
200d MA $66.77
P/E (TTM)
7.6x
EV/EBITDA
6.3x
P/B
—
Debt/Equity
-2.4x
ROE
-332.5%
P/FCF
8.6x
RSI (14)
—
ATR (14)
—
Beta
0.55
50d MA
$67.66
200d MA
$66.77
Avg Volume
1.3M
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
100 Corporate Court · Warren, NJ 07080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.45 | -0.03 | +93.3% | 64.49 | +14.9% | +14.3% | — | — | — | — | — |
| Feb 19, 2026 | AMC | -0.21 | -1.67 | -695.2% | 69.90 | -2.1% | +1.1% | +0.9% | -1.3% | -3.1% | -2.6% | — |
| Nov 4, 2025 | AMC | -1.19 | 0.20 | +116.8% | 67.72 | +3.4% | +6.0% | +7.2% | +6.0% | +7.0% | +9.0% | — |
| Aug 7, 2025 | AMC | -1.07 | -0.83 | +22.4% | 50.36 | -10.6% | -9.9% | -14.0% | -10.1% | -4.3% | -3.3% | — |
| May 6, 2025 | AMC | -1.08 | 10.04 | +1029.6% | 36.19 | +8.9% | +12.6% | +17.5% | +22.2% | +27.1% | +28.2% | — |
| Feb 27, 2025 | AMC | -1.12 | -0.24 | +78.6% | 50.57 | -10.1% | +9.3% | +4.5% | +2.4% | +2.7% | +4.4% | — |
| Nov 7, 2024 | AMC | -1.54 | -1.39 | +9.7% | 42.96 | +6.2% | +3.1% | +4.4% | +3.9% | +2.5% | -1.4% | — |
| Aug 8, 2024 | AMC | -1.00 | -1.16 | -16.0% | 32.45 | -9.5% | -3.6% | -3.5% | -1.8% | -2.1% | +1.8% | — |
| Apr 25, 2024 | AMC | -1.21 | -1.20 | +0.8% | 25.49 | +5.9% | +12.1% | +26.1% | +26.1% | +34.0% | +31.9% | — |
| Feb 29, 2024 | AMC | 0.29 | -0.24 | -182.8% | 28.19 | -6.0% | +13.3% | +9.9% | +11.0% | +9.5% | +9.1% | — |
| Oct 26, 2023 | AMC | -0.85 | -1.76 | -107.1% | 23.95 | -19.2% | -22.7% | -21.8% | -21.7% | -23.0% | -24.6% | — |
| Aug 3, 2023 | AMC | -1.58 | -2.66 | -68.4% | 40.32 | +1.9% | -4.0% | -5.8% | -3.2% | -1.2% | +0.8% | — |
| Apr 27, 2023 | AMC | -1.64 | -1.88 | -14.6% | 52.64 | +5.2% | +4.7% | +4.8% | +4.4% | +5.3% | +6.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 8 | TD Cowen | Upgrade | Hold → Buy | $90 | — | — | — | — | — | — | — | — |
| Mar 30 | Jefferies | Downgrade | Buy → Hold | — | $66.13 | $65.34 | -1.2% | -0.7% | +3.0% | +4.0% | +2.5% | +4.2% |
| Feb 23 | Morgan Stanley | Maintains | Overweight → Overweight | — | $70.66 | $69.98 | -1.0% | -0.2% | -2.4% | -4.1% | -3.6% | -3.5% |
| Feb 20 | Wells Fargo | Maintains | Overweight → Overweight | — | $69.90 | $68.45 | -2.1% | +1.1% | +0.9% | -1.3% | -3.1% | -2.6% |
| Feb 20 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $69.90 | $68.45 | -2.1% | +1.1% | +0.9% | -1.3% | -3.1% | -2.6% |
| Feb 20 | BofA Securities | Maintains | Buy → Buy | — | $69.90 | $68.45 | -2.1% | +1.1% | +0.9% | -1.3% | -3.1% | -2.6% |
| Jan 28 | Barclays | Upgrade | Equal Weight → Overweight | — | $75.49 | $76.87 | +1.8% | +0.1% | +1.2% | +0.1% | -0.8% | -0.9% |
| Dec 1 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $85.99 | $83.19 | -3.3% | -7.9% | -8.7% | -11.9% | -9.5% | -10.2% |
| Nov 6 | Barclays | Maintains | Equal Weight → Equal Weight | — | $71.77 | $71.79 | +0.0% | +1.1% | +0.0% | +1.0% | +2.9% | +4.4% |
| Nov 5 | Wells Fargo | Maintains | Overweight → Overweight | — | $67.72 | $70.00 | +3.4% | +6.0% | +7.2% | +6.0% | +7.0% | +9.0% |
| Nov 5 | Citigroup | Maintains | Neutral → Neutral | — | $67.72 | $70.00 | +3.4% | +6.0% | +7.2% | +6.0% | +7.0% | +9.0% |
| Nov 5 | TD Cowen | Maintains | Hold → Hold | — | $67.72 | $70.00 | +3.4% | +6.0% | +7.2% | +6.0% | +7.0% | +9.0% |
| Nov 5 | RBC Capital | Maintains | Outperform → Outperform | — | $67.72 | $70.00 | +3.4% | +6.0% | +7.2% | +6.0% | +7.0% | +9.0% |
| Nov 5 | Goldman Sachs | Maintains | Sell → Sell | — | $67.72 | $70.00 | +3.4% | +6.0% | +7.2% | +6.0% | +7.0% | +9.0% |
| Oct 28 | Jefferies | Maintains | Buy → Buy | — | $67.08 | $66.86 | -0.3% | +0.6% | +0.4% | +1.5% | +1.8% | +1.3% |
| Sep 3 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $52.43 | $52.88 | +0.9% | +6.0% | +10.6% | +9.2% | +8.6% | +11.4% |
| Aug 20 | BofA Securities | Maintains | Buy → Buy | — | $49.59 | $49.38 | -0.4% | -1.5% | -1.4% | +2.0% | -0.6% | -0.3% |
| Aug 20 | Morgan Stanley | Maintains | Overweight → Overweight | — | $49.59 | $49.38 | -0.4% | -1.5% | -1.4% | +2.0% | -0.6% | -0.3% |
| Aug 20 | Wells Fargo | Maintains | Overweight → Overweight | — | $49.59 | $49.38 | -0.4% | -1.5% | -1.4% | +2.0% | -0.6% | -0.3% |
| Aug 8 | Morgan Stanley | Maintains | Overweight → Overweight | — | $50.36 | $45.00 | -10.6% | -9.9% | -14.0% | -10.1% | -4.3% | -3.3% |
| Aug 8 | Wells Fargo | Maintains | Overweight → Overweight | — | $50.36 | $45.00 | -10.6% | -9.9% | -14.0% | -10.1% | -4.3% | -3.3% |
| Aug 8 | RBC Capital | Maintains | Outperform → Outperform | — | $50.36 | $45.00 | -10.6% | -9.9% | -14.0% | -10.1% | -4.3% | -3.3% |
| Jul 29 | BofA Securities | Maintains | Buy → Buy | — | $44.34 | $47.50 | +7.1% | +11.2% | +14.9% | +17.5% | +17.6% | +17.8% |
| Jul 29 | Barclays | Maintains | Equal Weight → Equal Weight | — | $44.34 | $47.50 | +7.1% | +11.2% | +14.9% | +17.5% | +17.6% | +17.8% |
| Jul 29 | Wells Fargo | Maintains | Overweight → Overweight | — | $44.34 | $47.50 | +7.1% | +11.2% | +14.9% | +17.5% | +17.6% | +17.8% |
| Jul 29 | Truist | Maintains | Buy → Buy | — | $44.34 | $47.50 | +7.1% | +11.2% | +14.9% | +17.5% | +17.6% | +17.8% |
| Jul 29 | UBS | Maintains | Buy → Buy | — | $44.34 | $47.50 | +7.1% | +11.2% | +14.9% | +17.5% | +17.6% | +17.8% |
| Jul 29 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $44.34 | $47.50 | +7.1% | +11.2% | +14.9% | +17.5% | +17.6% | +17.8% |
| Jul 28 | Citigroup | Maintains | Neutral → Neutral | — | $44.74 | $44.82 | +0.2% | -0.9% | +10.2% | +13.9% | +16.5% | +16.5% |
| May 27 | Wells Fargo | Maintains | Overweight → Overweight | — | $45.93 | $47.43 | +3.3% | +4.2% | +2.9% | +6.4% | +5.6% | +6.3% |
| May 9 | BofA Securities | Upgrade | Neutral → Buy | — | $42.51 | $44.29 | +4.2% | +4.0% | +8.2% | +9.1% | +10.0% | +6.6% |
| May 8 | Barclays | Maintains | Equal Weight → Equal Weight | — | $40.76 | $40.72 | -0.1% | +4.3% | +8.5% | +12.9% | +13.8% | +14.7% |
| May 7 | Baird | Maintains | Outperform → Outperform | — | $36.19 | $39.40 | +8.9% | +12.6% | +17.5% | +22.2% | +27.1% | +28.2% |
| May 7 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $36.19 | $39.40 | +8.9% | +12.6% | +17.5% | +22.2% | +27.1% | +28.2% |
| May 7 | RBC Capital | Maintains | Outperform → Outperform | — | $36.19 | $39.40 | +8.9% | +12.6% | +17.5% | +22.2% | +27.1% | +28.2% |
| May 7 | JP Morgan | Maintains | Overweight → Overweight | — | $36.19 | $39.40 | +8.9% | +12.6% | +17.5% | +22.2% | +27.1% | +28.2% |
| May 7 | Citigroup | Upgrade | Sell → Neutral | — | $36.19 | $39.40 | +8.9% | +12.6% | +17.5% | +22.2% | +27.1% | +28.2% |
| Apr 22 | RBC Capital | Maintains | Outperform → Outperform | — | $48.19 | $48.00 | -0.4% | +0.0% | +3.7% | +2.8% | +2.8% | +3.3% |
| Mar 31 | JP Morgan | Maintains | Overweight → Overweight | — | $54.24 | $52.89 | -2.5% | -6.0% | -14.1% | -10.8% | -13.8% | -20.3% |
| Mar 14 | JP Morgan | Maintains | Overweight → Overweight | — | $52.76 | $53.50 | +1.4% | +3.3% | +8.4% | +5.1% | +8.0% | +7.3% |
| Mar 11 | BofA Securities | Upgrade | Underperform → Neutral | — | $52.49 | $53.12 | +1.2% | +0.2% | +2.1% | +0.5% | +3.8% | +8.9% |
| Feb 28 | JP Morgan | Maintains | Overweight → Overweight | — | $50.57 | $45.45 | -10.1% | +9.3% | +4.5% | +2.4% | +2.7% | +4.4% |
| Feb 18 | RBC Capital | Maintains | Outperform → Outperform | — | $51.82 | $52.50 | +1.3% | -4.6% | -2.7% | -2.8% | -2.2% | -3.5% |
| Feb 12 | Citigroup | Maintains | Sell → Sell | — | $48.64 | $47.64 | -2.1% | +0.6% | +2.1% | +6.5% | +1.6% | +3.7% |
| Feb 3 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $45.88 | $45.86 | -0.0% | +9.0% | +7.6% | +9.0% | +8.5% | +7.8% |
| Jan 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $41.81 | $42.92 | +2.7% | +1.1% | +3.0% | +4.9% | +8.2% | +7.8% |
| Dec 13 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $47.36 | $49.34 | +4.2% | -2.1% | +2.6% | -0.7% | -4.0% | -4.5% |
| Dec 4 | Goldman Sachs | Maintains | Sell → Sell | — | $50.29 | $49.89 | -0.8% | -0.9% | -3.8% | -4.5% | -4.4% | -0.6% |
| Dec 4 | Citigroup | Maintains | Sell → Sell | — | $50.29 | $49.89 | -0.8% | -0.9% | -3.8% | -4.5% | -4.4% | -0.6% |
| Dec 3 | Barclays | Maintains | Equal Weight → Equal Weight | — | $52.07 | $53.33 | +2.4% | -3.4% | -4.2% | -7.0% | -7.7% | -7.7% |
No insider trades available.
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Morgan Stanley appointed a new executive (details in exhibit), which could signal strategic leadership changes affecting future direction and investor confidence in management's vision.
Mar 25
8-K
PTC Therapeutics, Inc. -- 8-K Filing
PTC Therapeutics reported strong Q4 2025 results and continued momentum from its Sephience product launch, signaling successful commercial execution and positive revenue growth trajectory for investors.
Feb 19
8-K · 7.01
! Medium
PTC Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
PTC Therapeutics withdrew its Translarna resubmission for nonsense mutation DMD after FDA feedback, eliminating a potential revenue driver and signaling development challenges for this therapy.
Feb 12
Data updated apr 26, 2026 9:07pm
· Source: massive.com